1. Generics Bulletin

March Uptick Suggests Reversal For Olainfarm

While ‘Substantial Results’ Seen From Distribution Alliance In Ukraine

 
• By Akriti Seth

Olainfarm says a change in its strategy has delivered an increase in sales March despite an overall decline in the first quarter of 2020. Turnover in Ukraine shot up as a result of a new distribution alliance.

Snowdrop_Flower
Olainfarm saw green shoots of recovery in March after a tough first quarter • Source: Shutterstock

Latvia’s Olainfarm group says changing its strategy has helped it to reverse a downward trend in the first quarter of 2020, with its results for the month of March alone showing sales growth of more than a fifth and contrasting with the turnover drop of almost a tenth seen for the firm across the entire three-month period.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.